CHELATED ZINC

Indications

• Constipation
• Dietary fiber supplementation
• Irritable bowel syndrome
• Diverticular disease
• Weight management

Dosage

Children: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Adults: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Mechanism of action

Cellulose acts primarily as a bulk-forming laxative. It absorbs water in the intestines, which increases stool bulk and stimulates peristalsis, thus facilitating bowel movements. Additionally, cellulose is not digestible by human enzymes, leading to fermentation by gut bacteria, which may enhance gut health and alter gut microbiota composition.

Pharmacodynamics

Cellulose increases stool weight and frequency of bowel movements. It works by retaining water in the intestines, leading to softer stools and improved passage through the gastrointestinal tract. The bulking effect of cellulose can help alleviate constipation and promote overall digestive health. It may also play a role in cholesterol reduction and glycemic control through its effects on digestion and absorption of nutrients.

Pharmacokinetics

Cellulose is not absorbed into the bloodstream due to its indigestible nature. Instead, it passes through the gastrointestinal tract, where it adds bulk to the stool. Its fermentation by colonic bacteria produces short-chain fatty acids, which may have beneficial effects on colon health. The onset of action for cellulose as a laxative can vary but is generally within 24 to 72 hours after ingestion.

Adverse effects

• Bloating
• Flatulence
• Diarrhea
• Abdominal discomfort

Precautions

• Use with caution in patients with a history of gastrointestinal disorders.
• Monitor for potential allergic reactions in sensitive individuals.

Pregnancy

Cellulose is generally considered safe during pregnancy as it is a non-toxic, indigestible fiber.

Breast-feeding

Cellulose is also considered safe during breastfeeding; it is excreted in breast milk in negligible amounts.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Capsules
• Tablets
• Granules

Pregnancy

There is limited data on the safety of color additives during pregnancy. Use only if clearly needed and after consultation with a healthcare provider.

Breast-feeding

The safety of color additives during breastfeeding is not well studied. Use with caution and consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Used as a disintegrant in tablet formulations
• Enhances the bioavailability of active pharmaceutical ingredients

Dosage

Children: Refer to the specific formulation guidelines, as dosage will vary based on the active ingredient and formulation type.

Adults: Refer to the specific formulation guidelines, as dosage will vary based on the active ingredient and formulation type.

Mechanism of action

Croscarmellose sodium works by swelling and absorbing water when it comes into contact with gastrointestinal fluids. This swelling leads to the rapid disintegration of the tablet or capsule matrix, facilitating the release and absorption of the active pharmaceutical ingredients.

Pharmacodynamics

Croscarmellose sodium is classified as a superdisintegrant. Its ability to rapidly disintegrate solid dosage forms can significantly enhance the dissolution rate of the active ingredient, which is crucial for achieving therapeutic effects in a timely manner.

Pharmacokinetics

Croscarmellose sodium is not absorbed in the gastrointestinal tract and does not exert pharmacological effects in the body. It is considered non-toxic and is excreted unchanged. Its main role is as an excipient, influencing the formulation's characteristics rather than the pharmacokinetics of the active ingredients.

Precautions

• Use with caution in patients with known hypersensitivity to croscarmellose or its components.

Pregnancy

Safety in pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Caution is advised when using during breastfeeding, as safety has not been established.

Storage

Store in a cool, dry place, away from moisture and heat.

Formulations

• Powder
• Granules

Indications

• Calcium deficiency
• Osteoporosis prevention
• Osteomalacia
• Rickets
• Dietary supplementation in individuals with increased calcium and phosphorus requirements

Dosage

Children: Refer to established guidelines for specific dosing based on clinical indications and individual patient needs.

Adults: Refer to established guidelines for specific dosing based on clinical indications and individual patient needs.

Mechanism of action

Dicalcium phosphate dissociates in the gastrointestinal tract to release calcium and phosphate ions. Calcium plays a vital role in various physiological processes, including muscle contraction, neurotransmitter release, and blood coagulation. The phosphate ions are essential for energy metabolism and are integral to the formation of ATP (adenosine triphosphate), nucleic acids, and cellular membranes. The availability of these ions supports bone mineralization and overall skeletal integrity.

Pharmacodynamics

The pharmacodynamics of dicalcium phosphate involves its role in maintaining calcium and phosphate homeostasis in the body. Adequate levels of calcium are critical for normal bone metabolism, while phosphate is necessary for the formation of hydroxyapatite in bone tissue. The balance of these minerals is regulated by hormones such as parathyroid hormone and calcitriol, which modulate their absorption in the intestines and reabsorption in the kidneys. Supplementation with dicalcium phosphate can help alleviate deficiencies and support bone health.

Pharmacokinetics

Dicalcium phosphate is absorbed in the gastrointestinal tract, with varying absorption rates depending on the presence of other dietary components. Calcium absorption occurs primarily in the small intestine, while phosphate absorption can occur throughout the gastrointestinal tract. After absorption, calcium is distributed to bones, teeth, and soft tissues, while excess calcium is excreted through urine. The pharmacokinetics may be influenced by factors such as age, dietary habits, and the presence of gastrointestinal disorders.

Adverse effects

• Gastrointestinal disturbances (nausea, constipation)
• Hypercalcemia
• Kidney stones
• Fatigue
• Muscle weakness

Interactions

• May interact with calcium channel blockers
• Increased risk of hypercalcemia with thiazide diuretics
• May affect the absorption of certain antibiotics (e.g., tetracyclines)

Precautions

• Use with caution in patients with renal impairment
• Monitor calcium levels in patients receiving high doses
• Consider potential interactions with other medications

Pregnancy

Dicalcium is generally considered safe in pregnancy when used as directed, but high doses should be avoided.

Breast-feeding

Calcium is an essential nutrient during breastfeeding, but excessive supplementation should be approached with caution.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Formulations

• Tablets
• Powders
• Chewable tablets

Indications

• Used as an excipient in pharmaceutical formulations
• Improves solubility and stability of active ingredients
• Facilitates drug absorption

Dosage

Children: Refer to specific product guidelines as hydroxypropyl is typically used as an excipient and not dosed independently.

Adults: Refer to specific product guidelines as hydroxypropyl is typically used as an excipient and not dosed independently.

Mechanism of action

Hydroxypropyl functions primarily as a solubilizing agent, which aids in the dissolution of poorly soluble drugs. It interacts with water and other solvents to improve the dispersion of pharmaceutical compounds, thereby enhancing their bioavailability. Hydroxypropyl may also facilitate the permeability of drug molecules through biological membranes, contributing to their overall efficacy.

Pharmacodynamics

The pharmacodynamics of hydroxypropyl relate to its role in improving the physicochemical properties of drug formulations. By increasing solubility and stability, hydroxypropyl can enhance the absorption of drugs administered via various routes, including oral and topical. Its non-toxic nature allows for safe incorporation into formulations, making it suitable for a wide range of applications.

Pharmacokinetics

The pharmacokinetics of hydroxypropyl have not been extensively studied as it primarily acts as an excipient rather than an active pharmaceutical ingredient. When used in formulations, it is typically not absorbed into systemic circulation in significant amounts, thereby minimizing potential systemic effects. Hydroxypropyl is generally regarded as safe when used in appropriate amounts in drug formulations.

Pregnancy

Hydroxypropyl is not classified for use during pregnancy, and its safety has not been established. Caution is advised.

Breast-feeding

There is limited information on the excretion of hydroxypropyl in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Pain relief
• Inflammatory conditions
• Dental applications
• Antifungal treatments
• Antioxidant support

Dosage

Children: Refer to specific product guidelines for pediatric dosing as it may vary based on formulation and intended use.

Adults: Refer to specific product guidelines as dosing may vary based on formulation and intended use.

Mechanism of action

The exact mechanism of action of eugenol is not fully understood. However, it has been shown to interrupt action potentials, contributing to its analgesic properties. Eugenol exhibits anti-inflammatory effects by modulating the activity of polymorphonuclear leukocytes, which release inflammatory mediators. Additionally, eugenol has demonstrated antioxidant activity, protecting cells from oxidative stress. It has been observed to inhibit the formation of malondialdehyde in irradiated thymocytes, suggesting a protective role against oxidative damage.

Pharmacodynamics

Eugenol exhibits several pharmacological properties, including analgesic, anti-inflammatory, antipyretic, neuroprotective, antifungal, and antioxidant effects. Its ability to inhibit reactive oxygen species generation and modulate inflammatory mediators contributes to its therapeutic potential in managing pain and inflammation. The dose-dependent effects of eugenol on respiratory inhibition of mitochondria highlight its impact on cellular energy metabolism, further extending its pharmacodynamic profile.

Pharmacokinetics

Eugenol is rapidly absorbed and distributed throughout the body following administration. It undergoes extensive metabolism in the liver, with various metabolic pathways including conjugation and oxidation. The elimination half-life and specific pharmacokinetic parameters can be influenced by the route of administration and individual patient factors. The exact pharmacokinetics of eugenol in humans require further elucidation through clinical studies.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Skin irritation
• Allergic reactions

Precautions

• Use with caution in individuals with liver disease or gastrointestinal disorders.
• Caution is advised in patients who are pregnant or breastfeeding.

Pregnancy

Eugenol should be used with caution during pregnancy due to insufficient data on safety.

Breast-feeding

Eugenol is excreted in breast milk; caution is advised when administering to breastfeeding mothers.

Storage

Store in a tightly closed container, in a cool, dry place away from light.

Formulations

• Essential oil
• Topical preparations

Dosage

Children: Refer to specific product guidelines or BNF for Children for detailed dosing information, as it varies based on the active ingredient.

Adults: Refer to specific product guidelines or BNF for detailed dosing information as it varies widely based on the active ingredient.

Mechanism of action

The mechanism of action for powdered drugs varies widely depending on the specific active ingredient included in the powder. For example, antibiotics may work by inhibiting bacterial cell wall synthesis, while analgesics may block pain pathways in the central nervous system. Generally, the powdered form allows for rapid dissolution and absorption once ingested or administered, leading to the desired pharmacological effect.

Pharmacodynamics

The pharmacodynamics of powdered medications are determined by the active compounds present. These drugs can exert their effects through various pathways, such as receptor binding, enzyme inhibition, or modulation of ion channels. The onset, duration, and intensity of action are influenced by the pharmacological properties of the active ingredient, including its potency and the body's sensitivity to the drug.

Pharmacokinetics

The pharmacokinetics of powdered drugs involve absorption, distribution, metabolism, and excretion (ADME). After administration, the powder is typically dissolved in the gastrointestinal tract, where it is absorbed into the bloodstream. Distribution occurs via systemic circulation and depends on factors such as solubility and plasma protein binding. Metabolism often occurs in the liver, where enzymes may modify the drug into active or inactive metabolites. Finally, excretion primarily occurs via the kidneys, although some drugs may also be eliminated through bile or feces.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to established dietary guidelines for children, as specific dosing for stearic acid is not typically defined.

Adults: Refer to established dietary guidelines and clinical recommendations for fatty acid intake, as specific dosing for stearic acid is not typically defined.

Mechanism of action

Stearic acid is metabolized in the liver and can be converted to oleic acid through a process called desaturation. It does not significantly affect cholesterol levels compared to other saturated fatty acids, as it can be converted into monounsaturated fatty acids. Stearic acid may also modulate signaling pathways involved in inflammation and metabolism.

Pharmacodynamics

Stearic acid exhibits various physiological effects, including modulation of lipid metabolism. It has been shown to influence the composition of cell membranes and can affect the fluidity and function of membranes due to its saturated structure. Stearic acid may also play a role in the regulation of gene expression related to lipid metabolism and inflammation.

Pharmacokinetics

Stearic acid is absorbed from the gastrointestinal tract and is incorporated into chylomicrons for transport in the bloodstream. It is metabolized primarily in the liver, where it undergoes beta-oxidation to produce energy. The elimination half-life and specific metabolic pathways may vary based on dietary intake and individual metabolic differences.

Pregnancy

There are no established guidelines regarding the use of stearic acid during pregnancy. Consultation with a healthcare provider is recommended.

Breast-feeding

There is limited information available on the use of stearic acid during breastfeeding. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Keep container tightly closed.

Formulations

• Capsules
• Tablets
• Powder
• Topical ointments

Mechanism of action

Triacetin functions primarily as a plasticizer, improving the flexibility and workability of polymers. In pharmaceutical formulations, it may enhance the solubility and stability of active ingredients, allowing for better drug delivery.

Pharmacodynamics

The pharmacodynamic properties of triacetin are associated with its role as a plasticizer, impacting the physical characteristics of polymeric materials. In a pharmaceutical context, it can improve the release profile of drugs from solid dosage forms, potentially enhancing bioavailability.

Pharmacokinetics

Triacetin is absorbed through the gastrointestinal tract and metabolized into glycerol and acetic acid. The elimination half-life and specific metabolic pathways in humans are not extensively characterized. It is known to undergo hydrolysis, resulting in the formation of glycerol and acetic acid, which are further utilized in metabolic processes.

Pregnancy

There is no specific information available regarding the use of triacetin during pregnancy. Caution is advised.

Breast-feeding

There is no specific information available regarding the use of triacetin during breastfeeding. Caution is advised.

Storage

Store in a well-closed container, at room temperature, away from direct sunlight and moisture.

Formulations

• {'formulation': 'Liquid', 'strength': 'Not specified'}

Mechanism of action

The exact mechanism of action of eugenol is unknown. However, eugenol has been shown to interrupt action potentials, which may be involved in its anti-pain activity. Research has also shown eugenol to have anti-inflammatory, neuroprotective, antipyretic, antioxidant, antifungal and analgesic properties. ... Thymocyte suspension was irradiated by gamma-rays, and the malondialdehyde (MDA) formation was measured with the thiobarbituric acid reactive species (TBARS) method. The results showed an increase in MDA in irradiated (2 Gy) thymocytes, which was inhibited in samples treated with increasing concentrations of eugenol (10-200 uM) prior to irradiation. The concentration of eugenol required to inhibit half of the MDA formation (IC(50)) in irradiated thymocytes was 100 uM. A dose-dependent increase in the generation of ROS was observed in irradiated thymocytes (0.5-200 cGy) as measured by 2,7-dichlorodihydro fluorescein diacetate (DCH-FDA), which was inhibited by eugenol administered before irradiation. Respiratory inhibition of isolated rat liver mitochondria by eugenol was dose related and uncoupled oxidative phosphorylation from electron transfer. Polymorphonuclear leukocytes (PMNL) play an important role in the modulation of inflammatory conditions in humans. PMNL cells recruited at the site of inflammation, release inflammatory mediators such as leukotrienes, proteolytic enzymes and reactive oxygen species. Among these, leukotrienes are implicated in pathophysiology of allergic and inflammatory disorders like asthma, allergic rhinitis, arthritis, inflammatory bowel disease and psoriasis. 5-lipoxygenase (5-LO) is the key enzyme in biosynthetic pathway of leukotrienes. Our earlier studies showed that spice phenolic active principles significantly inhibit 5-LO enzyme in human PMNLs. In this study we have further characterized the inhibitory mechanism of eugenol, the active principle of spice-clove on 5-LO enzyme and also its effect on leukotriene C((4)) (LTC(4)). Substrate dependent enzyme kinetics showed that the inhibitory effect of eugenol on 5-LO was of a non-competitive nature. Further, eugenol was found to significantly inhibit the formation of LTC(4) in calcium ionophore A23187 and arachidonic acid (AA) stimulated PMNL cells. These data clearly suggest that eugenol inhibits 5-LO by non-competitive mechanism and also inhibits formation of LTC(4) in human PMNL cells and thus may have beneficial role in modulating 5-LO pathway in human PMNL cells. The Ca(2+)-activated Cl(-) channel TMEM16A is involved in epithelial fluid secretion, smooth muscle contraction and neurosensory signaling. We identified a Thai herbal antidiarrheal formulation that inhibited TMEM16A Cl(-) conductance. C18-reversed-phase HPLC fractionation of the herbal formulation revealed >98% of TMEM16A inhibition activity in one out of approximately 20 distinct peaks. The purified, active compound was identified as eugenol (4-allyl-2-methoxyphenol), the major component of clove oil. Eugenol fully inhibited TMEM16A Cl(-) conductance with single-site IC(50)~150 uM. Eugenol inhibition of TMEM16A in interstitial cells of Cajal produced strong inhibition of intestinal contraction in mouse ileal segments. TMEM16A Cl(-) channel inhibition adds to the list of eugenol molecular targets and may account for some of its biological activities. For more Mechanism of Action (Complete) data for EUGENOL (21 total), please visit the HSDB record page.